Thermoablation of Bone Tumors
Thermoablation von Knochentumoren

Authors
K. I. Ringe1, M. Panzica2, C. von Falck1

Affiliations
1 Department of Diagnostic and Interventional Radiology, Medizinische Hochschule Hannover, Germany
2 Department of Trauma Surgery, Medizinische Hochschule Hannover, Germany

Key words
bones, laser, RFA, MWA, cryoablation, HIFU

Introduction
Image-guided percutaneous ablation is a well-established treatment method for primary and secondary tumors of parenchymatous abdominal organs, the lungs, and the musculoskeletal system. Chemical treatment methods have been distinguished from energy-based methods, based on the recommendations of the International Working Group on Image-Guided Tumor Ablation, which was developed in conjunction with the Cardiovacular and Interventional Radiological Society of Europe (CIRSE) [1]. Thermoablative techniques are the treatment of choice for ablation of tumors of the musculoskeletal system (Fig. 1).

The goal of all thermoablative procedures is to induce coagulation necrosis in the target tissue using special applicators (electrodes,
antennas, probes) placed in the tumor using image guidance. Depending on the procedure, the tissue is either cooled to below -20 °C (cryoablation) or heated to temperatures above 80 °C (hyperthermal ablation). The latter technique includes radiofrequency ablation (RFA), microwave ablation (MWA), laser ablation and high-intensity focused ultrasound (HIFU). During thermal ablation, the extent of coagulation necrosis is dependent upon three important factors: 1. The quantity of applied energy, 2. Local tissue interactions, 3. Losses of heating or cooling effects (most significant is the so-called heat sink effect) [2]. The individual techniques exhibit specific advantages and disadvantages that will be described in more detail below. Selection of the imaging method for placing the applicators depends on the method of treatment, the operator’s preference as well as the availability of equipment. Computed tomography (CT) or magnetic resonance imaging (MRI) are primarily used in the course of thermal ablation of bone tumors. The first part of this review article describes the technical basics of the various thermoablative procedures; the second section discusses curative and palliative indications for thermal ablation of bone tumors.

Thermoablative Procedures

Radiofrequency Ablation (RFA)
At present RFA is the most widespread and most thoroughly evaluated thermoablative procedure. This technique uses a 150 – 250 watt generator to generate alternating current that oscillates between the radiofrequency (RF) electrode (cathode) inserted in the tumor and a neutral electrode on the body surface (unipolar system). When using a bipolar system, application of a neutral electrode is unnecessary, since the RF electrode functions as a cathode as well as an anode. While the current in this circuit oscillates in the tissue via ion channels, frictional processes at the tip of the RF electrode create heat (Joule effect), thereby destroying adjacent tumor tissue. The associated dehydration in the target tissue leads to an increase of tissue resistance during ablation thus limiting energy application, and the resulting ablation area exhibits limited expansion [3]. Depending on tumor size, quantity and location, one or more RF electrodes can be utilized; however, the electrodes may differ in design depending on the manufacturer (needle, umbrella or cluster electrodes) (Table 1). By additionally applying a temperature measurement probe, continuous monitoring of the tissue temperature can be performed during RFA as well as during MWA.

Internal cooling of the electrodes during ablation, as is possible with most of the available systems, thus guarantees more effective and homogeneous energy distribution. Particularly when compared to early MWA systems, RFA provides well reproducible necrosis zones. Additional technical implementations, such as the development of expandable probes (also called umbrella electrodes) to increase the electrode surface, application of pulsed energy as well as saline solution likewise contribute to producing homogeneous necrosis during RFA with predictable results.

Microwave Ablation (MWA)
During MWA a generator is used to produce a high-frequency electromagnetic field (915 MHz or 2.45 GHz) at the tip of the antenna inserted into the tumor. The result is interaction between the applied energy field and the intrinsic water dipoles in the adjoining tissue which have the tendency to arrange themselves continuously along the energy field. Rotation of the water molecules thereby generates kinetic energy and consequently frictional heat. MWA thus relies not on the flow of current, but rather on an electromagnetic field, and is thus largely independent of changes in tissue resistance. Consequently, compared to RFA, higher intratumoral temperatures (> 150 °C) are achieved, associated with shortening of the ablation time and reduced heat loss in the tissue [4].

This is advantageous, particularly with respect to the previously-mentioned heat sink effect, a known phenomenon limiting the effectiveness of all thermoablative procedures. Blood vessels (diameter ≥3 mm) that pass through the ablation zone or lie directly adjacent have a cooling effect, thus negatively affecting local heat transmission. As a consequence there can be incomplete ablation of tumor tissue adjoining these blood vessels with the risk of local tumor recurrence or progression. Current studies have shown that the heat sink effect is also present during MWA, although in reduced form compared to RFA, since this procedure directly heats a greater volume of tissue, and peripheral

---

Table 1

<table>
<thead>
<tr>
<th>Techniques used for image-guided percutaneous thermal ablation. (modified from [1]).</th>
</tr>
</thead>
<tbody>
<tr>
<td>▶ Fig. 1</td>
</tr>
</tbody>
</table>
heat transfer is less significant [5, 6]. A further advantage over RFA is the fact that application of a neutral electrode is not required. Analogously to RFA, most available MWA systems provide internal cooling of the antennas during ablation thus providing more homogeneous energy distribution (‘‘Table 1’’). Furthermore, current studies have shown that in addition to RFA, MWA can be used on pacemaker patients without complication; however, close collaboration with a cardiologist is recommended in order to avoid malfunctions of the implant [7]. Compared to RFA, potential disadvantages of MWA particularly include higher material costs. Depending on the manufacturer, the wiring is relatively rigid and harder to handle. In addition, the antennas are often very flexible which can impede exact positioning during the procedure. Since during ablation of bone tumors, the lesion is generally first drilled and then the antenna is inserted coaxially, this latter aspect plays an important role primarily in the treatment of parenchymatous organs.

**Laser Ablation**

Laser ablation (formerly: laser-induced interstitial tumor therapy, LIITT) is likewise a hyperthermal ablation procedure that is based on the effect of electromagnetic radiation with a wavelength in the near infrared range. Due to the good penetration qualities in the tissue, the most common energy sources are Nd:YAG (neodymium-doped yttrium aluminum garnet) or semiconductor conduction /diode lasers with a wavelength of 1064 nm or 800–1000 nm [8]. The photon-induced tissue heating, using the protein denaturing mechanism, results in coagulation necrosis and thus cell death. The very thin laser fibers (200–600 µm) can be inserted into the tissue coaxially using an 18 gauge needle or via a special applicator system. The size of the ablation zone during laser therapy depends on the size of the optical fiber, wavelength, thermal and optical characteristics of the tissue as well as the output and duration of the laser application [9]. Compared to other thermoablative procedures, the ablation volume generated by a single fiber is relatively small. Small bone lesions such as osteoid osteoma are therefore a very good indication for laser ablation. Several laser fibers can be simultaneously inserted to produce larger ablation zones. Likewise, internal cooling of the applicators prevents carbonization, thus leading to an enlargement of the ablation zone. The advantage is

<table>
<thead>
<tr>
<th>system</th>
<th>manufacturer</th>
<th>generator</th>
<th>applicator specifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>RFA</td>
<td>AMICA-GEN HS Amica</td>
<td>200 W; 450 kHz (+/-2.45 GHz), dual generator for RFA and MWA available</td>
<td>unipolar, 17 G; active tip 10, 20 or 30 mm</td>
</tr>
<tr>
<td>1500X</td>
<td>AngioDynamics</td>
<td>250 W; 460 kHz</td>
<td>unipolar, 14 G, 17 G; umbrella or needle electrode; MRI-compatible electrode available</td>
</tr>
<tr>
<td>RF 3000</td>
<td>Boston Scientific</td>
<td>200 W; 480 kHz</td>
<td>unipolar; umbrella electrode array diameter: 20–50 mm; needle electrode: active tip 9 mm</td>
</tr>
<tr>
<td>CoolTip E-Series</td>
<td>Covidien</td>
<td>200 W; 480 kHz</td>
<td>unipolar, 17 G; active tip 7–30 mm; single or cluster electrode</td>
</tr>
<tr>
<td>STAR</td>
<td>DFINE</td>
<td>10 W; 480 kHz</td>
<td>bipolar; 11 G, special for spine; angulated tip max. 41 mm</td>
</tr>
<tr>
<td>CelonLab POWER</td>
<td>Olympus</td>
<td>250 W; 470 kHz</td>
<td>bipolar; 15 G; needle electrode; active tip: 20–40 mm; MRI-compatible electrode available</td>
</tr>
<tr>
<td>MWA</td>
<td>AMICA-GEN HS Amica</td>
<td>max. 140 W; 2.45 GHz</td>
<td>11, 14, 16 G, max. 2 antennas simultaneously</td>
</tr>
<tr>
<td>Acculis</td>
<td>AngioDynamics</td>
<td>max. 140 W; 2.45 GHz</td>
<td>15 G; active tip 28 mm</td>
</tr>
<tr>
<td>Evident</td>
<td>Covidien</td>
<td>45 W; 915 kHz</td>
<td>14 G; active tip: 20 or 37 mm; max. 3 antennas simultaneously</td>
</tr>
<tr>
<td>Emprint</td>
<td>Covidien</td>
<td>max. 100 W; 2.45 GHz</td>
<td>13 G; active tip 28 mm</td>
</tr>
<tr>
<td>MicroThermX</td>
<td>Terumo</td>
<td>max. 180 W; 915 kHz</td>
<td>14 G; active tip 20 or 41 mm; max. 3 antennas simultaneously</td>
</tr>
<tr>
<td>laser ablation</td>
<td>Medilas Fibertom 8100</td>
<td>100 W; Nd:YAG laser; wave length 1064 nm</td>
<td>400 µm, 600 µm</td>
</tr>
<tr>
<td>Model 25</td>
<td>Diomed</td>
<td>25 W; diode laser; wave length 805 nm</td>
<td>400 µm</td>
</tr>
<tr>
<td>cryoablation</td>
<td>PerCryo</td>
<td>argon for cooling, helium for thawing</td>
<td>1.7 – 2.4 mm; multiple probe configurations; simultaneous ablation with up to max. 8 probes</td>
</tr>
<tr>
<td></td>
<td>Visual-ICE, Presice,</td>
<td>argon for cooling, helium for thawing; thawing process possible without add. helium tank; MRI-compatible system available</td>
<td>1.5 or 2.4 mm; 17 G; active tip up to 47 mm length; multiple probe configurations; simultaneous ablation with up to max. 25 probes</td>
</tr>
<tr>
<td></td>
<td>SeedNet, SeedNet MRI</td>
<td>Gall Medical</td>
<td>1.5 or 2.4 mm; 17 G; active tip up to 47 mm length; multiple probe configurations; simultaneous ablation with up to max. 25 probes</td>
</tr>
<tr>
<td>MRgHIFU</td>
<td>ExAblate 2000</td>
<td>InSightec</td>
<td>mobile patient table compatible only with general electric scanners (1.5 or 3 T)</td>
</tr>
<tr>
<td></td>
<td>Sonalleve MR-HIFU</td>
<td>Philips Healthcare</td>
<td>mobile patient table compatible only with Phillips healthcare scanners (1.5 or 3 T)</td>
</tr>
</tbody>
</table>

RFA = Radiofrequency Ablation; MWA = Microwave Ablation, MRgHIFU = MR-guided High Intensity Focused Ultrasound.
that the laser fibers do not interact with pacemakers or other metallic implants. Moreover, the MRI compatibility of the systems, as is also the case for individual RF systems (Table 1), permits temperature monitoring during ablation while at the same time avoiding radiation exposure of the patients who are often young.

**High-intensity Focused Ultrasound (HIFU)**

High-intensity focused ultrasound (HIFU) is a comparatively new and non-invasive technique during which ultrasound waves with frequencies in the low megahertz range (17 MHz) are focused on a small target volume while neighboring organs and structures are spared. The mechanical energy of the sound wave is thus transformed into thermal energy, achieving temperatures above 90 °C. The ability to target tissue deep in the body depends on the frequency and intensity of the sound wave as well as the characteristics of the tissue lying between the piezoelectric transducer and target volume [10]. In addition to thermal damage in the target volume, the introduced ultrasonic pulse (sonication) causes mechanical effects, namely gas formation (cavitation effect). Due to this, brief pauses between individual sonications are necessary to avoid uncontrolled reflections and deformation of the ultrasound beam. A prerequisite for this is a free acoustic window, since gas, air and bone interfere with the propagation of the sound wave, as is already known from diagnostic ultrasound. Related border areas can absorb the sound wave with the risk of incomplete treatment of the tumor, cavitation effects as well as the hazard of burns to intervening tissue [9].

MR-guided HIFU (MRgHIFU) has been approved by the FDA and European Union for palliative treatment of bone lesions. Cortical bone is characterized by a high absorption of ultrasound and low thermal conductivity. This is an advantage in the treatment of painful bone metastases, since the maximum energy deposition occurs in the region of periosteal localized pain fibers [11]. On the whole, the procedure is quite time-consuming since the resulting ablation area is relatively small (between 50 and 300 mm²). Larger target volumes can be treated using a combination of several ablation areas [12]. Currently two MRgHIFU systems have been approved in Europe; however, they are compatible only with individual MRI devices (Table 1).

**Cryoablation**

In contrast with hyperthermal ablation procedures, during cryoablation, the tumor tissue is cooled to temperatures below -20 °C. Energy transfer from the inserted probe into the surrounding tissue is achieved by means of conduction and convection, the latter mechanism among other things is dependent on heat transfer through adjacent blood vessels (counterpart to the heat sink effect, the so-called “cool sink” effect) [13]. The cryoablation probes have two chambers and are filled with compressed gases. Depending on the inversion temperature of the gases used, the Joule-Thomson effect results in a change in temperature as soon as the gases expand in the space surrounding the probe tip. For example, the inversion temperature of argon, nitrogen or oxygen is above room temperature such that when these gases expand, the temperature falls (cooling effect). The inversion temperature of hydrogen and helium is below room temperature; consequently the temperature rises as the gases expand [14]. Correspondingly, most clinical ablation systems employ compressed argon and helium for cooling and thawing, respectively; in such uses, temperatures below -140 °C are achieved [15] (Table 1).

During ablation, the “ice ball” at the tip of the probe can be visualized directly, an advantage over other ablation techniques, for example during treatment of lesions adjoining critical structures (nerves, blood vessels) [16]. Whereas the diameter of the ice ball is essentially a function of the energy transfer rate (and thus dependent upon the flow rate of gas through the probe), the length of the ice ball is dependent upon the length of the non-insulated probe. It should be kept in mind that the boundary of the ice ball visible in the CT represents the 0 °C isotherm which is not lethal. In order to guarantee a complete ablation of the target lesion, the boundary of the ice ball should extend at least 5 mm beyond the lesion itself. Simultaneous application of multiple probes can correspondingly increase the ablation area [14]. A further advantage of cryoablation is its intrinsic analgesic effect which results in the patient experiencing less pain during and immediately after treatment compared to hyperthermal ablation techniques [16].

**Thermal Ablation of benign Bone Tumors**

**Osteoid osteoma**

Osteoid osteoma is a bone-forming lesion, comprising about 10 % of all bone tumors, primarily affecting children and youths between the ages of 10 and 25 years, with a predominance among males. Osteoid osteoma is histologically characterized by a central nidus made of osteoblasts and osteoid with peripheral nerve and vascular supply [17]. Excessive production of prostaglandins in the nidus results in local inflammatory response, hyperemia and abnormal bone growth [18]. Primary sites are the cortical long bones (primarily femur and tibia); approx. 10 % of lesions are found in the axial skeleton, more rarely on the hands and feet. Clinically, osteoid osteoma is characterized by pain, occurring mainly at night, and typically responds to acetylsalicylic acid (ASA) or nonsteroidal anti-inflammatory drugs (NSAIDs). Depending on the location, there can be occurrences of stunting, bone deformity, painful scoliosis or muscle atrophy. Diagnosis is made based on clinical observation in combination with typical image-based findings (Fig. 2). Osteoid osteoma exhibits a very low tendency to grow. A conservative therapeutic approach with ASA or NSAIDs can provide simultaneous diagnostic indications. Prior to establishing minimally-invasive treatment procedures, surgical resection in the form of enbloc resection or curettage represents the primary mode of therapy with a success rate between 88 and 100 %. However, the invasiveness of these procedures involves complication rates of up to 35 % (curettage) and 45.5 % (resection) [19, 20]. Furthermore, the location in the bone of the generally small nidus can make surgery very difficult (Fig. 3).

Employing image-guided minimally-invasive treatment methods (CT-guided drilling, ablation) is advantageous both with respect to sparing adjacent structures as well as localizing the lesion during the procedure. CT-guided drilling of the nidus can be performed alone or in combination with an injection of ethanol. According to the literature, the success rate lies between 77 and 100 %; the complication rate is up to 24 % [21]. However, recurrences are more fre-
quent due to incomplete removal of the nidus. In addition, the alcohol distribution is more difficult to control which can result in damage to adjoining structures.

Nowadays, percutaneous thermal ablation, used to completely destroy the nidus, represents the method of choice for the treatment of osteoid osteoma (Fig. 4). Since the patients are usually relatively young, the procedure is commonly performed under general anesthesia. Drilling the bone or nidus to place the applicators is performed manually employing coaxial systems or using an electric drill. Simultaneously, the diagnosis can be confirmed through biopsy; however biopsy is not necessary for diagnostic purposes, and depending on the size of the underlying study cohort, confirms the diagnosis only in 38 – 100% of cases [22, 23]. The manufacturers’ recommendations should be relied upon for the ablation protocol for the respective system. At our institution, we usually perform RFA under general anesthesia. Ablation is performed for 8 minutes at a target temperature of 80 °C for unipolar RFA using a non-cooled needle electrode. If the nidus is greater than 1 cm, it is recommended to perform a second ablation cycle after an additional access path has been drilled with related repositioning of the applicator. Immediately after the procedure, pain symptoms may increase; therefore, good peri-interventional pain management is recommended. The patient can be mobilized directly after the procedure; success can be evaluated based on a clinical examination two weeks later. If symptoms persist or recur, repeated ablation is the method of choice; however the results of repeated ablation are usually worse in case of initial lack of symptoms. Relative contraindications for thermal ablation can depend on the location of the osteoid osteoma as well as the experience of the interventionist. Lesions in the region of the hand, feet or spinal column present special situations if they are located within less than 1 cm from vital structures (e.g. nerves). Injections of air, CO2 or glucose can separate critical structures, thereby increasing the safety during the procedure [24].

With respect to therapeutic success, the various thermoablative techniques are practically equal (Table 2). RFA provides the greatest evidence for ablation of osteoid osteoma; this procedure was first described in 1992 by Rosenthal...
et al. [25]. The primary success rates indicated in the literature are 87 – 96%. Overall success rates due to recurring symptoms lie between 91 – 99%. Compared with all other procedures, the complication rate during percutaneous ablation is very low. In a systematic review article in 2009, out of 996 ablations, 29 complications were described, primarily involving burns, material breakage and local inflammatory response [26]. For laser ablation, the primary and secondary success rates are 92 – 96% and 97 – 100%, respectively, comparable to those of RFA. Potential advantages of

**Table 2** Overview of studies (selection) evaluating percutaneous thermal ablation methods for treating osteoid osteoma.

<table>
<thead>
<tr>
<th>technique</th>
<th>design</th>
<th>location</th>
<th>pat. [n]</th>
<th>PSR [%]</th>
<th>SSR [%]</th>
<th>compl.</th>
<th>FU</th>
<th>reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>cryo</td>
<td>case report</td>
<td>extremities, thorax</td>
<td>2</td>
<td>100</td>
<td></td>
<td>0</td>
<td>20.5 months</td>
<td>Liu et al 2010 [51]</td>
</tr>
<tr>
<td>cryo</td>
<td>retrospective</td>
<td>extremities</td>
<td>6</td>
<td>100</td>
<td></td>
<td>0</td>
<td>28.7 months</td>
<td>Wu et al 2011 [52]</td>
</tr>
<tr>
<td>cryo</td>
<td>retrospective</td>
<td>extremities, pelvis</td>
<td>10</td>
<td>100</td>
<td></td>
<td>0</td>
<td>24 weeks</td>
<td>Coupal et al 2014 [31]</td>
</tr>
<tr>
<td>laser</td>
<td>retrospective</td>
<td>extremities, spine, ribs</td>
<td>114</td>
<td>95</td>
<td>99.1</td>
<td>1</td>
<td>58.5 months</td>
<td>Gangi et al 2007 [27]</td>
</tr>
<tr>
<td>laser</td>
<td>retrospective</td>
<td>extremities (hand, foot)</td>
<td>15</td>
<td>93.3</td>
<td>100</td>
<td>0</td>
<td>49.9 months</td>
<td>Zouari et al 2008 [53]</td>
</tr>
<tr>
<td>laser</td>
<td>retrospective</td>
<td>extremities, pelvis</td>
<td>100</td>
<td>96</td>
<td>98</td>
<td>4</td>
<td>47 months</td>
<td>Roqueplan et al 2010 [54]</td>
</tr>
<tr>
<td>laser</td>
<td>retrospective</td>
<td>extremities, pelvis</td>
<td>35</td>
<td>94.3</td>
<td>97</td>
<td>4</td>
<td>40 months</td>
<td>Etienne et al 2013 [55]</td>
</tr>
<tr>
<td>laser</td>
<td>retrospective</td>
<td>extremities, pelvis</td>
<td>25</td>
<td>92</td>
<td>n.a.</td>
<td>5</td>
<td>26 months</td>
<td>Aschero et al 2009 [56]</td>
</tr>
<tr>
<td>MRgFUS</td>
<td>retrospective</td>
<td>n.a.</td>
<td>9</td>
<td>83</td>
<td></td>
<td>0</td>
<td>1 – 3 months</td>
<td>Napoli et al 2013 [57]</td>
</tr>
<tr>
<td>MRgFUS</td>
<td>prospective</td>
<td>extremities</td>
<td>29</td>
<td>90</td>
<td>n.a.</td>
<td>0</td>
<td>12 months</td>
<td>Geiger et al 2014 [30]</td>
</tr>
<tr>
<td>MWA</td>
<td>retrospective</td>
<td>extremities, thorax</td>
<td>10</td>
<td>100</td>
<td></td>
<td>0</td>
<td>8.6 months</td>
<td>Basile et al 2014 [28]</td>
</tr>
<tr>
<td>RFA</td>
<td>retrospective</td>
<td>extremities, pelvis, spine</td>
<td>97</td>
<td>76</td>
<td>92</td>
<td>2</td>
<td>41 months</td>
<td>Vand erschueren et al 2002 [22]</td>
</tr>
<tr>
<td>RFA</td>
<td>meta-analysis</td>
<td>extremities, pelvis, spine</td>
<td>912</td>
<td>87</td>
<td>95</td>
<td>29</td>
<td>n.a.</td>
<td>Bruners et al 2009 [26]</td>
</tr>
<tr>
<td>RFA</td>
<td>retrospective</td>
<td>extremities</td>
<td>557</td>
<td>96</td>
<td>99.6</td>
<td>5</td>
<td>3.5 years</td>
<td>Rimondi et al 2012 [58]</td>
</tr>
<tr>
<td>RFA</td>
<td>retrospective</td>
<td>extremities, pelvis, spine</td>
<td>263</td>
<td>89</td>
<td>91</td>
<td>2</td>
<td>&gt; 24 months</td>
<td>Rosenthal et al 2013 [59]</td>
</tr>
<tr>
<td>RFA</td>
<td>retrospective</td>
<td>extremities, pelvis, spine</td>
<td>87</td>
<td>89.6</td>
<td>97.5</td>
<td>7</td>
<td>34 months</td>
<td>Bourgault et al 2014 [60]</td>
</tr>
<tr>
<td>RFA</td>
<td>retrospective</td>
<td>extremities, axial skeleton</td>
<td>79</td>
<td>92</td>
<td>98.7</td>
<td>3</td>
<td>45.6 months</td>
<td>Own cohort</td>
</tr>
</tbody>
</table>

PSR = Primary Success Rate; SSR = Secondary Success Rate after re-intervention; Compl. = Complications; FU = Average Follow-up; Cryo = Cryoablation, Laser = Laser Ablation; MRgFUS = MR-guided Focused Ultrasound Surgery; MWA = Microwave Ablation; RFA = Radiofrequency Ablation; n.a. = not indicated.

**Fig. 3** 47-year-old female patient with persistent pain in the right humerus three months following alleged resection of an osteoid osteoma. On postoperative radiography A the defect (*) can be clearly visualized. The nidus (arrow) however is located further distal and has not been resected. The patient was referred for RFA. On CT (perinterventional scan in the sagittal B and axial plane C, D) the nidus is clearly identified. The patient was free from pain following the day after the procedure.
laser ablation can be shown for the treatment of lesions on small bones of the hands and feet due to the relative small path of access (18G) and good predictability of the resulting ablation zone [27]. When directly compared to RFA, MWA offers potential methodological and technical advantages that have been discussed at the beginning of this article; it can be presumed that the clinical results should be similar. However, there are to date only two studies in which a total of 17 patients have been treated using MWA [28, 29]. The situation is similar regarding studies of MRgHIFU treatment of osteoid osteoma. A prospective multi-center study describes a clinical success rate of 90% for this completely non-invasive procedure [30]. However, the authors of this study emphasize the importance of accurate localization of the lesion, since the general limitation of this method poses the risk of damage to adjoining neutral structures. Due to its intrinsic analgesic effect and the visualization characteristics of the ice ball during ablation, the use of cryoablation for treating osteoid osteoma is obvious. Intra- and post-operative pain is not as pronounced compared to e.g. RFA, so that treatment can also be performed under sedation [16, 31]. Interestingly, there have to date been no large-scale published studies demonstrating the long-term clinical success of cryoablation.
Rare Indications
Recently published studies indicated promising results, particularly for minimally-invasive treatment of osteoblastoma such that now RFA is currently regarded as the method of choice over surgical treatment [7, 32]. Experiences regarding percutaneous thermal ablation of other bone tumors are limited and rely mainly on case reports or small case series, examples of which include the treatment of chondroblastoma [33], eosinophilic granuloma [34] or desmoid tumors [35]. In individual cases, indication for this treatment can be provided due to a difficult local tumor situation, if surgical resection would involve extended damage to adjacent structures, for example [36], or if the patient refuses surgery. Indications for ablation in all cases should be provided after taking into account all interdisciplinary therapeutic alternatives.

Thermal Ablation of malignant Bone Tumors
Bone metastases
The most frequent malignant bone tumors include metastases with primary tumor particularly of the breast, prostate or kidney. Pain as the cardinal symptom affects up to 80% of patients [37]. In this context, the long-term effects of untreated, or insufficiently treated pain, should be kept in mind in addition to the acute symptoms. Such long-term effects particularly include limitations of mobility and reduced quality of life, anxiety and depression as well as the risk of pathological fracture [37]. Traditional therapeutic options for treating bone metastases include medicinal approaches, radiation and surgical procedures and depend on the tumor histology, quantity and location. Despite the availability of various therapeutic approaches, not all patients benefit equally from these treatment options. Among other things, varying radio sensitivity of different tumors and the latency period until the maximum effect of the treatment sets in should be kept in mind [38]. Surgical alternatives are invasive and, depending upon location and the tumor, involve a high morbidity rate and long postoperative hospitalization [39]. There are therapeutic shortcomings in the general concept of the treatment of bone metastases. Initial, mainly retrospective studies have described excellent clinical results for percutaneous thermal ablation of bone metastases. For example, Thanos et al. could achieve pain reduction in 19 of 30 patients within 24 hours after RFA. Within a week, all patients reported significant pain reduction.
should be performed critically (41) (Patient selection for effective treatment of bone metastases and bone treatment of the boundary surfaces between the tumor neous thermal ablation is palliation of pain via targeted α tion of osteoclast-activating factors (e.g. interleukins, TNF-receptors, tumor cell destruction as well as reduced secre-duction is based on thermal destruction of pain fibers and life (40). The effect of ablation to achieve immediate pain re-
duction, together with an improvement of their quality of life (40). The effect of ablation to achieve immediate pain re-
duction is based on thermal destruction of pain fibers and receptors, tumor cell destruction as well as reduced secre-
tion of osteoclast-activating factors (e.g. interleukins, TNF-
α, endothelins). In this regard, the primary goal of percuta-
neous thermal ablation is palliation of pain via targeted treatment of the boundary surfaces between the tumor and bone (Fig. 5). Tumor debulking, i.e., mass reduction, is only a secondary consideration. Since there may be an ini-
tial increase in pain symptoms immediately after treat-
ment, sufficient peri- and post-interventional pain man-
agement should be employed, using a PCA pump if needed (Fig. 6).

Patient selection for effective treatment of bone metastases should be performed critically (41) (Table 3). The most suitable patients are those indicating pain greater than 4 points on the 10-point visible analog scale (VAS), but with no more than two predominant pain locations. The treat-
ment of osteolytic metastases in weight-bearing regions can be combined with cementoplasty to minimize the risk of pathological fracture. Less suitable are patients with dis-
seminated painful metastases. Lesions with the risk of frac-
ture should primarily undergo surgical therapy. Tumors with a distance less than 1 cm from critical structures such as the spinal cord or large blood vessels represent a relative contra-indication, if it is not possible to isolate these struc-
tures via protective means (e.g. air, CO2 or glucose). In most studies, osteoblastic metastases have not been shown to be suitable, even though treatment can be successful in individual cases (42, 43).

In the meantime, the literature provides clear evidence that ablation of painful bone metastases effectively contributes to pain reduction. Analogously to the treatment of benign bone lesions, the various thermoablative techniques are comparable with respect to their result (Table 4); the advantages and disadvantages of the individual procedures discussed in the previous sections likewise apply. Thus, for example, cryoablation, when directly compared to RFA, shows potential advantages with respect to the direct post-
interventional pain symptoms (44). Guglielmi et al. compared effects of cryoablation plus cementoplasty with RFA plus cementoplasty in the treatment of 30 osteolytic bone metastases (45). With respect to the therapeutic result measured by means of the visual analog scale, no significant difference was found in the time frame of one week to six months after the treatment. However, the immediate treat-
ment-associated pain in the early post-interventional phase was less pronounced after ablation. In this context using only cement injection or vertebroplasty can be expedient. The synergistic chemical, thermal and mechanical effects of the injected cement (generally polymethylmethacrylate, PMMA) can result in significant reduction of pain in pa-
patients with osteolytic metastases of the spine (46). However, most studies indicate that a longer-lasting benefit resulted from combinational therapy, e.g. cryoablation plus verteb-
roplasty (47). The supplemental injection of cement offers the advantage of immediate stabilization.

Rare Indications

The treatment of primary malignant bone tumors is princi-
pally surgical, with accompanying systemic therapy as needed. An interdisciplinary approach can employ percu-
taneous ablation, such as in the case of lesions that are located in anatomically unfavorable sites, inoperability or recurrence. Evidence in the literature regarding the effect-
iveness in selected cohorts is limited in this respect, how-
ever. For example, Yamakado et al. performed RFA on 52 pa-
tients with recurrent osteo- or soft tissue sarcoma; in 40.4 % of these cases complete ablation was achieved (48). The

Table 3: Patient selection criteria for palliative percutaneous thermal ablation of painful bone metastases (adapted from [41]).

<table>
<thead>
<tr>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Localizable pain &gt; 4/10 on the VAS</td>
<td>Disseminated painful metastases</td>
</tr>
<tr>
<td>Max. two dominant pain locations due to bone metastases</td>
<td>Risk of fracture of target bone</td>
</tr>
<tr>
<td>Life expectancy &gt; 2 months</td>
<td>(Osteoblastic metastases)</td>
</tr>
<tr>
<td>Capable of agreeing to procedure (lesion &lt; 1 cm distant from critical structures)</td>
<td>Coagulation (PTT &lt; 50 s, Quick &gt; 50 s, platelets &gt; 50,000 / µl)</td>
</tr>
</tbody>
</table>

VAS = Visual Analog Scale; PTT = Partial Thromboplastin Time.
The effectiveness of ablation is less dependent on the size of bone metastases for palliation of pain is effective and safe and effective pain palliation. Cryo + cement retrospective mixed osteolytic extremities, spine 74 curative treatment possible in individual cases Deschamps et al 2014 [62]

Overall survival rate after 1, 3 and 5 years was 73.4%, 39.3% and 34.4%, respectively. Using ultrasound-guided HIFU, Chen et al. treated 80 patients with bone tumors (osteosarcoma, chondrosarcoma, Ewing sarcoma, giant cell tumor). In combination with systemic chemotherapy, the survival of patients with stage 2b tumor disease was thereby significantly improved. In addition to individual case reports in the literature such as the treatment of aneurysmal bone cysts or giant cell tumors, when pain is in the forefront of symptoms, percutaneous ablation can additionally be employed in the palliation of primary bone tumors, analogously to the treatment of bone metastases [50].

**Summary**

Various techniques can be used for percutaneous thermal ablation of bone tumors, each of which offers specific advantages and disadvantages. Percutaneous ablation is the therapy of choice for the treatment of osteoid osteoma, due to the relatively lower complication rate, shorter rehabilitation time and lower costs, combined with a very high success rate, when compared to surgery. Percutaneous ablation of bone metastases for palliation of pain is effective and should be integrated into existing therapeutic concepts. The effectiveness of ablation is less dependent on the size of the lesion, but rather should be related to the specific indication, which should be limited to patients with well-localized pain. Indications for treatment of other benign and malignant bone tumors are present in individual cases due to a tumor-specific situation and should be reviewed by an interdisciplinary tumor board.

**References**

Kostrzewa M, Basile A, 2011: 15–26


